Pages that link to "Q43965189"

The following pages link to Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. (Q43965189):

Displaying 28 items.

• Discussing the diagnosis of HPV-OSCC: common questions and answers (Q27000693) (← links)
• Plant-made vaccines for humans and animals. (Q30386732) (← links)
• Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. (Q33840918) (← links)
• The immunology of animal papillomaviruses (Q33848178) (← links)
• Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report (Q34089078) (← links)
• Hepatitis E: an overview and recent advances in vaccine research. (Q34334086) (← links)
• Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. (Q34353473) (← links)
• Papillomavirus-like particle based vaccines: cervical cancer and beyond (Q34451862) (← links)
• Vaccines for viral diseases with dermatologic manifestations (Q35131573) (← links)
• Oral immunogenicity of human papillomavirus-like particles expressed in potato (Q35182055) (← links)
• Progress in prophylactic and therapeutic vaccines for human papillomavirus infection (Q35194178) (← links)
• New approaches for the management of cervical cancer (Q35226253) (← links)
• Preventative and therapeutic vaccines for cervical cancer (Q35623323) (← links)
• Delivering on the promise: HPV vaccines and cervical cancer (Q35697573) (← links)
• Production of human papillomavirus type 16 virus-like particles in transgenic plants (Q35802720) (← links)
• Vaccination strategies for the prevention of cervical cancer (Q36066161) (← links)
• A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response (Q36673310) (← links)
• Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization (Q37391175) (← links)
• Human papillomavirus vaccines in plants (Q37776720) (← links)
• Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit (Q38606892) (← links)
• Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles (Q40608378) (← links)
• Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses (Q40762506) (← links)
• A Virus-based Vaccine May Prevent Cervical Cancer (Q45508177) (← links)
• Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice (Q45737415) (← links)
• Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses (Q56959423) (← links)
• Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector (Q57560056) (← links)
• [Anti-papillomavirus vaccines and prevention of cervical cancer: progress and prospects] (Q80387504) (← links)
• Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes (Q81151717) (← links)